CINCINNATI--(BUSINESS WIRE)--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide
release of SensiFAST Genotyping Kit, which has been specifically
developed for the important field of genotyping.
Bioline’s SensiFAST Genotyping Kit has been developed for fast, precise,
and highly reproducible genotyping of sequence variants, including loci
with type IV SNPs. With outstanding allele clustering, the SensiFAST
Genotyping Kit gives exceptional confidence in genotype calling with
probe-based real-time PCR SNP detection applications. The kit has been
validated on all commonly used instruments and features fast protocol
times, making it ideal for high-throughput workflows.
Marco Calzavara, President of Bioline commented, "I am delighted to
announce the release of another new research tool as part of the
SensiFAST family, our rapidly expanding real-time PCR range. Bioline is
dedicated to increasing the applications of our industry-leading
real-time PCR portfolio tools. The SensiFAST Genotyping Kit will enable
researchers to cost-effectively scan DNA from a variety of biological
samples to detect the smallest genetic variations among samples.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated,
“The release of the SensiFAST Genotyping Kit is part of a new generation
of products to advance the rapidly expanding portfolio of highly
specialized molecular biology reagents from Bioline. We remain committed
to our life science customers to bring innovation and quality products
to the research lab, clinical diagnostic laboratories, and biotechnology
companies.”
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life
science company that manufactures, markets and distributes a broad range
of innovative diagnostic test kits, purified reagents and related
products and offers biopharmaceutical enabling technologies. Utilizing a
variety of methods, these products and diagnostic tests provide
accuracy, simplicity and speed in the early diagnosis and treatment of
common medical conditions, such as gastrointestinal, viral and
respiratory infections. Meridian’s diagnostic products are used outside
of the human body and require little or no special equipment. The
Company's products are designed to enhance patient well-being while
reducing the total outcome costs of healthcare. Meridian has strong
market positions in the areas of gastrointestinal and upper respiratory
infections, serology, parasitology and fungal disease diagnosis. In
addition, Meridian is a supplier of rare reagents, specialty biologicals
and related technologies used by biopharmaceutical companies engaged in
research for new drugs and vaccines. The Company markets its products
and technologies to hospitals, reference laboratories, research centers,
veterinary testing centers, diagnostics manufacturers and biotech
companies in more than 60 countries around the world. The Company’s
shares are traded through NASDAQ’s Global Select Market, symbol VIVO.
Meridian's website address is www.meridianbioscience.com.
ADDITONAL INFORMATION
For more information about Bioline, please
visit www.bioline.com
For
more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For
more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Richard
L. Eberly, rick.eberly@meridianbioscience.com
Meridian Bioscience, Inc.
Richard L. Eberly, 513-271-3700
Source: Meridian Bioscience, Inc.
